RemeGen Co

RemeGen Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of RemeGen Co (688331.SS) as of Oct 26, 2026 is 9.95 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -26.47 % — a change of -137.60% (higher).

EBIT/Assets

9.95 %

YoY

-137.60%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of RemeGen Co is 2025 9.95 % . Operating Income to Assets Ratio (EBIT/Assets) of RemeGen Co was 2024 -26.47 % . It decreases by -137.60% higher compared to the previous year.

The RemeGen Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-45.79 CNY
Jan 1, 2019
-61.09 CNY
Jan 1, 2020
-17.19 CNY
Jan 1, 2021
3.92 CNY
Jan 1, 2022
-16.53 CNY
Jan 1, 2023
-27.16 CNY
Jan 1, 2024
-26.47 CNY
Jan 1, 2025
9.95 CNY
The RemeGen Co EBIT/Assets history
YEAREBIT/AssetsYoY
9.95 %-137.60%
-26.47 %-2.53%
-27.16 %+64.32%
-16.53 %-522.19%
3.92 %-122.78%
-17.19 %-71.87%
-61.09 %+33.43%
-45.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Operating Income to Assets Ratio (EBIT/Assets) of RemeGen Co is 9.95 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of RemeGen Co changed from -26.47 % to 9.95 %, representing a -137.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s RemeGen Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — RemeGen Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — RemeGen Co